Company profilePharmaceutical#176 of 1,318 in Pakistan2 DRAP alerts

AMSON VACCINES & PHARMA (PVT) LTD.

Pharmaceutical company · 102 brands · 132 molecules

Ranked #11 of 17 companies in Vaccine

102 registered products 41 pharmaceutical brands 132 distinct molecules 2 DRAP alerts

Company overview

102
registered products
41
pharmaceutical brands
132
distinct molecules
10
therapeutic classes
2
DRAP alerts

AMSON VACCINES & PHARMA (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 102 product registrations across 132 distinct molecules. It is the 176th largest registrant in Pakistan by product count, and ranks 11th of 17 in Vaccine. Its portfolio is concentrated in Vaccine and Antiinflammatory And Antirheumatic Products. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by AMSON

121 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

111
ceilings with an approval date
12
not revised in 2+ years
2024
oldest approval year
202412
20254
202695
Longest without revision

Top molecules by brand count

Therapeutic classes

Vaccine · 2Antiinflammatory And Antirheumatic Products · 1Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 1Opioids · 1Other Beta-Lactam, Cephalosporins & Penems · 1Antianemic, Folic Acid · 1Tonic · 1Blood Conditions · 1Macrolides, Lincosamides And Streptogramins · 1Bile And Liver Therapy · 1

Conditions treated

Anaemia · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official55 products · Rs 16.98 – Rs 19,803.3
DVAGO1 products · Rs 92.2 – Rs 92.2
Servaid2 products · Rs 300 – Rs 400
Median across source: Rs 254.7

Regulatory record

2 alerts in the DRAP feed we track.

Recall Alert: RECALL OF PRODUCTS CONTAINING HYDROXYPROGESTERONE CAPROATE
2025-06-23
Drug Safety Alert: Risk of Respiratory Failure and Sepsis with Terlipressin.
2023-10-26

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 107 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmoxicillinAmoxycillin BaseAnastrozole
BIO LABS (PVT) LTD. holds 113 molecules not in this portfolio
AprepitantAremetherArtesunateAscorbic AcidAzathioprineAzithromycin 250Mg
Atco Pharma International (Pvt) Ltd holds 207 molecules not in this portfolio
AcyclovirAdapaleneAdapleneAlbuterolAmlodipine 6.95Mg Amlodipine BaseAmlodipine,Atorvastatin Calcium

Get the full profile for AMSON

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.